OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Subrata Ghosh; Brian G. Feagan; Elyssa Ott; Christopher Gasink; Colleen Marano; Ye Miao; W. J. Sandborn; Silvio Danese; Maria T. Abreu; Bruce E. Sands

doi:10.1093/ecco-jcc/jjac190.0039

OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Subrata Ghosh
, Brian G. Feagan
, Elyssa Ott
, Christopher Gasink
, Colleen Marano
, Ye Miao
, W. J. Sandborn
, Silvio Danese
, Maria T. Abreu
, Bruce E. Sands

Western University
Janssen Scientific Affairs, LLC
Janssen Scientific Affairs, LLC
University of California at San Diego
Vita-Salute San Raffaele University
University of Miami
Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Long-term efficacy of ustekinumab (UST) has been reported in Crohn’s disease (CD) through 5 years (yrs)1 and in ulcerative colitis (UC) through 4 yrs.2 A previous pooled analysis of long-term safety data reported a favorable UST safety treatment profile for inflammatory bowel disease (IBD).3 Here, we present results of the final cumulative analysis of long-term safety data from UST studies through up to 5 yrs in CD and 4 yrs in UC.

Original language	English
Journal	Journal of Crohn's and Colitis
DOIs	https://doi.org/10.1093/ecco-jcc/jjac190.0039
Publication status	Published - 30 Jan 2023
Event	18th Congress of ECCO Copenhagen - Copenhagen, Denmark Duration: 1 Mar 2023 → 4 Mar 2023

Keywords

Medicine
Ustekinumab
Adverse effect
Safety profile
Nausea
Inflammatory bowel disease
Internal medicine
Pediatrics
Surgery
Disease
Infliximab

Access to Document

10.1093/ecco-jcc/jjac190.0039Licence: Unspecified

Cite this

@article{aaaddf95e9da4ff68a3464906c041340,

title = "OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC",

abstract = "Long-term efficacy of ustekinumab (UST) has been reported in Crohn{\textquoteright}s disease (CD) through 5 years (yrs)1 and in ulcerative colitis (UC) through 4 yrs.2 A previous pooled analysis of long-term safety data reported a favorable UST safety treatment profile for inflammatory bowel disease (IBD).3 Here, we present results of the final cumulative analysis of long-term safety data from UST studies through up to 5 yrs in CD and 4 yrs in UC.",

keywords = "Medicine, Ustekinumab, Adverse effect, Safety profile, Nausea, Inflammatory bowel disease, Internal medicine, Pediatrics, Surgery, Disease, Infliximab",

author = "Subrata Ghosh and Feagan, \{Brian G.\} and Elyssa Ott and Christopher Gasink and Colleen Marano and Ye Miao and Sandborn, \{W. J.\} and Silvio Danese and Abreu, \{Maria T.\} and Sands, \{Bruce E.\}",

year = "2023",

month = jan,

day = "30",

doi = "10.1093/ecco-jcc/jjac190.0039",

language = "English",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

note = "18th Congress of ECCO Copenhagen ; Conference date: 01-03-2023 Through 04-03-2023",

}

TY - JOUR

T1 - OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

AU - Ghosh, Subrata

AU - Feagan, Brian G.

AU - Ott, Elyssa

AU - Gasink, Christopher

AU - Marano, Colleen

AU - Miao, Ye

AU - Sandborn, W. J.

AU - Danese, Silvio

AU - Abreu, Maria T.

AU - Sands, Bruce E.

PY - 2023/1/30

Y1 - 2023/1/30

N2 - Long-term efficacy of ustekinumab (UST) has been reported in Crohn’s disease (CD) through 5 years (yrs)1 and in ulcerative colitis (UC) through 4 yrs.2 A previous pooled analysis of long-term safety data reported a favorable UST safety treatment profile for inflammatory bowel disease (IBD).3 Here, we present results of the final cumulative analysis of long-term safety data from UST studies through up to 5 yrs in CD and 4 yrs in UC.

AB - Long-term efficacy of ustekinumab (UST) has been reported in Crohn’s disease (CD) through 5 years (yrs)1 and in ulcerative colitis (UC) through 4 yrs.2 A previous pooled analysis of long-term safety data reported a favorable UST safety treatment profile for inflammatory bowel disease (IBD).3 Here, we present results of the final cumulative analysis of long-term safety data from UST studies through up to 5 yrs in CD and 4 yrs in UC.

KW - Medicine

KW - Ustekinumab

KW - Adverse effect

KW - Safety profile

KW - Nausea

KW - Inflammatory bowel disease

KW - Internal medicine

KW - Pediatrics

KW - Surgery

KW - Disease

KW - Infliximab

UR - https://openalex.org/W4318539915

U2 - 10.1093/ecco-jcc/jjac190.0039

DO - 10.1093/ecco-jcc/jjac190.0039

M3 - Meeting abstract

SN - 1873-9946

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

T2 - 18th Congress of ECCO Copenhagen

Y2 - 1 March 2023 through 4 March 2023

ER -

OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this